港股上市公司百奥赛图-B（02315）今日盘中大涨5.82%，引发市场广泛关注。这一显著涨幅主要源于公司近期发布的2024年度业绩报告，显示公司财务状况明显改善，成功实现扭亏为盈。
根据公司公告，百奥赛图2024年全年实现营收9.80亿元人民币，同比增长36.8%；净利润3353.7万元，相较去年同期亏损3.83亿元实现扭亏为盈。值得注意的是，公司净经营活动现金流入达2.11亿元，财务健康度大幅提升。这一业绩表现超出市场预期，显示公司已成功进入可持续增长的新发展阶段。
分析人士指出，百奥赛图的强劲表现主要得益于其抗体发现业务的高速增长。2024年该业务板块营收达3.18亿元，同比增长80.7%。公司"千鼠万抗"计划进入快速收获期，全年新增签署约100项药物合作开发/授权/转让协议。此外，公司积极布局AI驱动的抗体药物研发平台，有望为未来业务发展注入新动力。在生物科技行业整体复苏和AI技术发展的双重推动下，百奥赛图作为兼具稀缺性与成长性的优质标的，其估值有望进一步提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.